Imaging Study for FdCyd and THU Cancer Treatment

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

EARLY_PHASE1

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-01

Study Completion Date

2019-01-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

\- The drugs FdCyd (also called 5-fluoro-2'-deoxycytidine) and THU (also called tetrahydrouridine) are being used in a cancer treatment study. Not a lot is known about how FdCyd works in the body. Researchers want to look at a modified form of FdCyd using imaging studies to see how the drug reacts with the cancer. This study is not a treatment study. It is open only to people who are already on the FdCyd and THU cancer treatment study.

Objectives:

\- To study how FdCyd affects advanced cancer cells.

Eligibility:

\- Participants in National Cancer Institute study 09-C-0214.

Design:

* Participants will have two imaging studies, one before starting FdCyd and THU treatment and one after starting treatment.
* Participants will have the modified FdCyd, known as F-18 FdCyd, with a dose of THU. The doses will be followed by two imaging study scans and frequent blood samples.
* This procedure will be repeated at a later date, during the FdCyd and THU treatment period.
* Treatment will not be provided as part of this study. This is an imaging study protocol only....

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

NCT00757549

Head and Neck Cancer

COMPLETED EARLY_PHASE1

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

NCT03604315

Breast Carcinoma Fallopian Tube Carcinoma Ovarian Carcinoma +5 more

RECRUITING PHASE1

18-F-Fluoroacetate as PET Imaging Agent

NCT01320787

Brain Cancer Breast Cancer Prostate Cancer

WITHDRAWN PHASE1

18F-FMAU PET/CT in Imaging Patients With Advanced Cancers

NCT02079181

Malignant Neoplasm

TERMINATED NA

First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging

NCT05335811

Endocrine Neoplasia

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND:

\- In pre-clinical models, 5-fluoro-2-deoxycytidine (FdCyd), administered along with

tetrahydrouridine (THU; an inhibitor of cytidine/deoxycytidine deaminase), has shown superior anti-tumor activity as compared with 5-fluorouracil.

\- FdCyd can be phosphorylated to 5-fluoro-2-deoxycytidylate (FdCMP) by deoxycytidine

kinase and the nucleotide deaminated to FdUMP by deoxycytidylate (dCMP) deaminase.

The activity of dCMP deaminase is reported to be higher in human malignancies than in normal tissues, which may result in selective cytotoxicity.

* FdCyd is an inhibitor of deoxyribonucleic acid (DNA) methyltransferase and DNA methylation, resulting in reexpression of genes silenced by DNA hypermethylation. It is being evaluated in a phase II multihistology clinical trial at the Developmental Therapeutics Clinic, National Cancer Institute (NCI), Clinical Center, National Institutes of Health (NIH).
* While FdCyd + THU has shown preliminary evidence of activity in early phase trials not all patients show clinical response. The establishment of a radiolabeled form to image the biodistribution in vivo at baseline and during therapy may provide insight into the distribution of the therapeutic drug.
* The first step in the development of such an in vivo marker is to determine the

biodistribution and safety of the radiolabeled form.

OBJECTIVES:

* Determine the safety of \[F-18\]-5-fluoro-2'-deoxycytidine (FdCyd) administered intravenously with administration of tetrahydrouridine (THU).
* Estimate the radiation dosimetry of \[F-18\]-FdCyd in humans.

ELIGIBILITY:

* Only patients enrolled in NCI Phase II Study evaluating FdCyd with THU (NCI Protocol # 09-C-0214 (CTEP# 8351) or NCI Protocol #12-C-0066 (CTEP# 9127)) at the NIH Clinical Center will be eligible to participate in this study).
* Patients must have a target lesion greater than or equal to 10mm
* May not be pregnant or lactating; must be less than or equal to 350 lbs; and may not have known allergy to FdCyd or contraindications to positron emission tomography (PET)/computed tomography (CT) imaging.

DESIGN:

* There are two arms to this study
* The first arm will be patients enrolling in the therapeutic Phase II 5-FdCyd/THU study (NCI Protocol # 09-C-0214 (CTEP# 8351) in the NCI Developmental Therapeutics Clinic
* The second arm will be patients enrolling in the Phase I 5-FdCyd/THU study (NCI Protocol #12-C-0066 (CTEP# 9127)) in the NCI Developmental Therapeutics Clinic.
* Patients will undergo an initial \[F-18\]-FdCyd + THU PET/CT imaging prior to therapeutic dosing on study NCI Protocol # 09-C-0214 (CTEP# 8351) or NCI Protocol #12-C-0066 (CTEP# 9127). Repeat imaging will be performed while the patient is receiving FdCyd + THU therapy under the parent therapeutic protocol. This imaging must be completed 2-5 days after cycle start and at least 2 hours after a dose. Upon completion of repeat imaging, patients will be taken off this imaging study 24 hours after the last imaging session.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Head and Neck Neoplasms Lung Neoplasms Urinary Bladder Neoplasms Breast Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1/Intravenous (IV) Tetrahydrouridine (THU)

\[F-18\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine

Group Type EXPERIMENTAL

[F-18]-5-FLUORO-2'-DEOXYCYTIDINE

Intervention Type DRUG

18FdCyd radiotracer

Tetrahydrouridine intravenous (IV)

Intervention Type DRUG

Total dose of THU = 350 mg/m\^2, IV

Tetrahydrouridine (oral)

Intervention Type DRUG

Total dose of THU is 3000 mg, oral

Positron emission tomography (PET)/Computed tomography (CT)

Intervention Type DIAGNOSTIC_TEST

One prior CT and 3 sequential whole body PET

2/Oral Tetrahydrouridine (THU)

\[F-18\]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine

Group Type EXPERIMENTAL

[F-18]-5-FLUORO-2'-DEOXYCYTIDINE

Intervention Type DRUG

18FdCyd radiotracer

Tetrahydrouridine intravenous (IV)

Intervention Type DRUG

Total dose of THU = 350 mg/m\^2, IV

Tetrahydrouridine (oral)

Intervention Type DRUG

Total dose of THU is 3000 mg, oral

Positron emission tomography (PET)/Computed tomography (CT)

Intervention Type DIAGNOSTIC_TEST

One prior CT and 3 sequential whole body PET

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[F-18]-5-FLUORO-2'-DEOXYCYTIDINE

18FdCyd radiotracer

Intervention Type DRUG

Tetrahydrouridine intravenous (IV)

Total dose of THU = 350 mg/m\^2, IV

Intervention Type DRUG

Tetrahydrouridine (oral)

Total dose of THU is 3000 mg, oral

Intervention Type DRUG

Positron emission tomography (PET)/Computed tomography (CT)

One prior CT and 3 sequential whole body PET

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

18FdCyd THU THU PET scan/CT scan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Enrolled in the National Institutes of Health (NIH) Phase II Clinical protocol evaluating 5-fluro-2'-deoxycytidine (FdCyd) with Tetrahydrouridine (THU) (09-C-0214) with target lesion measured as greater than or equal to 10mm with spiral computed tomography (CT) scan.
* Written, voluntary, informed consent of the patient must be obtained in compliance with institutional, state and federal guidelines
* For females: Negative serum pregnancy test OR post-menopausal for at least 2 years OR patient has had a hysterectomy

Exclusion Criteria

* Participants with severe claustrophobia unresponsive to oral anxiolytics
* Subjects weighing \> 400 lbs (weight limit for scanner table), or unable to fit within the imaging gantry
* Known allergy to FdCyd
* The subject is unable to lie still for 75 minutes
* 5 Pregnant or lactating women. Pregnant women are excluded from this study because the effects of 18F-FdCyd in pregnancy are not known. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of 18F-FdCyd in the mother, breastfeeding should be discontinued if the mother receives 18F-FdCyd
* Participants with any co-existing medical or psychiatric condition that is likely to interfere with study procedures and/or results

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No